RxDoctor Payments DataLook up a doctor →

Agostino Ingraldi, MD

Interventional Cardiology · Lafayette, LANPI 1427254432

Payments from drug & device makers

$315,113in general payments, 2019–2025

Across 837 payments — averaging $376.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$127K
  • Johnson & Johnson$69K
  • Lilly USA, LLC$64K
  • Amgen$27K
  • Esperion Therapeutics, Inc.$14K
  • Abiomed$6K
  • plus $8K from 39 others

What the payments were for

  • Consulting fees$6,9252%
  • Speaking & faculty fees$260,55483%
  • Travel & lodging$30,31610%
  • Food & beverage$17,3145%
  • Education$40%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$315,113 in reported general payments places this provider in the 90th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$1,688,537
Medicare patients
2,776
Services billed
15,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,114$912,573
XareltoRivaroxaban730$620,252
Repatha SureclickEvolocumab524$376,277
EntrestoSacubitril/Valsartan233$208,713
JardianceEmpagliflozin107$110,714
Rosuvastatin Calcium4,231$54,574
VascepaIcosapent Ethyl102$53,947
Praluent PenAlirocumab80$52,691
NexlizetBempedoic Acid/Ezetimibe75$38,726
Ezetimibe1,913$33,370
Metoprolol Succinate1,596$19,947
Atorvastatin Calcium1,953$18,807
NexletolBempedoic Acid46$18,738
Repatha SyringeEvolocumab23$18,230
LivaloPitavastatin Calcium23$16,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$716$912,5731,114 claims
Johnson & JohnsonXarelto$68,932$620,252730 claims
NovartisEntresto$1,375$208,713233 claims
Boehringer IngelheimJardiance, Pradaxa$126,928$113,766122 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$14,311$57,463121 claims
Kowa Pharmaceuticals America, Inc.Livalo$298$16,16223 claims
Arbor Pharmaceuticals, Inc.Edarbi$151$9,85232 claims
AstraZenecaBrilinta$264$9,49112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →